positive
Healthcare startup MedGenome submits DRHP for ₹500 crore IPO focused on rare‑disease genomics
On 18 November 2025, genomic‑diagnostics firm MedGenome filed its Draft Red‑Herring Prospectus (DRHP) for an IPO of up to ₹500 crore. The company specialises in rare‑disease genomics and has a recurring revenue model servicing hospitals, research institutes and biopharma clients across India and Southeast Asia. Analysts said the issue could attract attention from healthcare‑tech funds given the niche focus, while broader market conditions remain cautious.
The company plans to expand its sequencing‑capacity and launch new precision‑medicine services after listing.
Explore:Mutual Fund Categories
positive
Healthcare startup MedGenome submits DRHP for ₹500 crore IPO focused on rare‑disease genomics
On 18 November 2025, genomic‑diagnostics firm MedGenome filed its Draft Red‑Herring Prospectus (DRHP) for an IPO of up to ₹500 crore. The company specialises in rare‑disease genomics and has a recurring revenue model servicing hospitals, research institutes and biopharma clients across India and Southeast Asia. Analysts said the issue could attract attention from healthcare‑tech funds given the niche focus, while broader market conditions remain cautious.
The company plans to expand its sequencing‑capacity and launch new precision‑medicine services after listing.
Explore:Mutual Fund Categories
Breaking
positive
Healthcare startup MedGenome submits DRHP for ₹500 crore IPO focused on rare‑disease genomics
1 min read
78 words
MedGenome filed its DRHP on 18 Nov for a ₹500 crore IPO, targeting rare‑disease genomics and expanding diagnostics capacity across Asia.
On 18 November 2025, genomic‑diagnostics firm MedGenome filed its Draft Red‑Herring Prospectus (DRHP) for an IPO of up to ₹500 crore. The company specialises in rare‑disease genomics and has a recurring revenue model servicing hospitals, research institutes and biopharma clients across India and Southeast Asia. Analysts said the issue could attract attention from healthcare‑tech funds given the niche focus, while broader market conditions remain cautious.
The company plans to expand its sequencing‑capacity and launch new precision‑medicine services after listing.
On 18 November 2025, genomic‑diagnostics firm MedGenome filed its Draft Red‑Herring Prospectus (DRHP) for an IPO of up to ₹500 crore. The company specialises in rare‑disease genomics and has a recurring revenue model servicing hospitals, research institutes and biopharma clients across India and Southeast Asia. Analysts said the issue could attract attention from healthcare‑tech funds given the niche focus, while broader market conditions remain cautious.
The company plans to expand its sequencing‑capacity and launch new precision‑medicine services after listing.
Companies:
MedGenome
Tags:
ipo
MedGenome
ipo
MedGenome
genomics
health‑tech
DRHP